IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data on its preclinical IDO, TDO and IDO/TDO Dual Inhibitor programs at the Keystone Tumor Immunology Symposium in Banff, Alberta, Canada, on February 10, 2015. IOmet has identified multiple, distinct novel chemical series of potent, IDO-selective, TDO-selective and dual-acting IDO/TDO inhibitors. These compounds demonstrate highly favourable in vitro human and rodent PK properties, which translate to robust in vivo PK/PD relationships.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
